ArticleAtherosclerosis2021
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
Article in Atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- The Association Between Abnormal Electrocardiogram Findings and the Ankle Brachial Index.Medicina (Kaunas, Lithuania) · 2026Article
- Associations of daily sedentary time and physical activity with risk of polyvascular disease in older adults.BMC public health · 2026Article
- Association between systemic inflammation indices and carotid plaques in acute coronary syndrome.Frontiers in cardiovascular medicine · 2026Article
- Impact of atherosclerotic cardiovascular disease on mortality in ICU sepsis patients: a retrospective MIMIC-IV cohort study.BMJ open · 2025Article
- Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Polyvascular Disease.Cardiology and therapy · 2025Article
- Impact of polyvascular disease severity on acute heart failure prognosis.Heart and vessels · 2025Article
- Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease - a secondary analysis of the randomized TWENTE trials.International journal of cardiology. Heart & vasculature · 2025Article
- Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Comparative analysis of cardiogenic shock outcomes in acute myocardial infarction with polyvascular disease.American heart journal plus : cardiology research and practice · 2024Article
- Diabetes and Its Impact on Cardiogenic Shock Outcomes in Acute Myocardial Infarction with Polyvascular Disease: A Comparative Analysis.Biomedicines · 2024Article
- Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.Cardiovascular diabetology · 2024Observational
- Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment.Current cardiology reports · 2024Review
- A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review: Part I-Epidemiology, Risk Factors, and Atherosclerosis-Related Diversities in Elderly Patients.Journal of clinical medicine · 2024Review
- Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry.European heart journal. Quality of care & clinical outcomes · 2023Article
- A Risk-Stratification Machine Learning Framework for the Prediction of Coronary Artery Disease Severity: Insights From the GESS Trial.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsPolyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabetes (T2D) is also understudied. Furthermore, it is unknown whether heart failure (HF) status and hemoglobin A1c (HbA1c) levels influence outcomes in polyvascular disease. This analysis from the Exenatide Study of Cardiovascular Event Lowering trial (EXSCEL) aimed to examine the risk associated with increasing number of diseased arterial beds on MACE and all-cause mortality (ACM).
methodsCox models were used to test associations between the number of diseased arterial beds and MACE and ACM. Prespecified interaction testing between number of diseased arterial beds with baseline HF, HbA1c (≤8% vs. >8%), and treatment assignment was performed.
resultsOverall, 14,751 participants were included; 26.5% were without atherosclerosis, 58.9% had 1-bed, 12.3% had 2-bed, and 2.3% had 3-bed disease. An increasing burden of atherosclerotic disease was associated with increasing risk of MACE (adjusted HR [aHR] 1.71 [95% CI 1.46-2.02]; 2.61 [2.17-3.15]; 3.46 [2.69-4.45] for 1, 2, and 3 beds, respectively, p < 0.001 for all) and ACM (1.94 [1.56-2.42]; 3.03 [2.33-3.95]; 3.66 [2.59-5.18] for 1, 2, and 3 beds, respectively, p < 0.001 for all). Prespecified interaction testing did not reveal any significant associations.
conclusionsIn patients with T2D, compared to those without atherosclerotic vascular disease, risk of MACE and ACM increases incrementally with each additional diseased arterial bed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.